Global 'side effects' of the EU's pharmaceutical reforms and their impact on access to medicines in LMICs.
作者信息
Perehudoff Katrina
机构信息
Law Centre for Health and Life, University of Amsterdam, Amsterdam, Netherlands
Amsterdam Centre for European Law and Governance, University of Amsterdam, Amsterdam, Netherlands.
出版信息
BMJ Glob Health. 2025 Apr 29;10(4):e017789. doi: 10.1136/bmjgh-2024-017789.
Abstract
摘要
相似文献
1
Global 'side effects' of the EU's pharmaceutical reforms and their impact on access to medicines in LMICs.欧盟药品改革的全球“副作用”及其对低收入和中等收入国家药品可及性的影响。
BMJ Glob Health. 2025 Apr 29;10(4):e017789. doi: 10.1136/bmjgh-2024-017789.
2
From Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access.从愿景到现实：欧盟的药品改革与改善可及性之路。
Pharmacoecon Open. 2025 May;9(3):331-339. doi: 10.1007/s41669-024-00556-w. Epub 2025 Jan 25.
3
Is the EU shirking responsibility for its deforestation footprint in tropical countries? Power, material, and epistemic inequalities in the EU's global environmental governance.欧盟是否在逃避其在热带国家森林砍伐足迹方面的责任？欧盟全球环境治理中的权力、物质和认知不平等。
Sustain Sci. 2023;18(2):599-616. doi: 10.1007/s11625-023-01302-7. Epub 2023 Feb 18.
4
The Biosimilar Revolution: Assessing the European Union's Approach to Biosimilarity, Interchangeability, Patient Access, and Its Market Analysis.生物类似药革命：评估欧盟对生物相似性、可互换性、患者可及性及其市场分析的方法。
Cureus. 2024 Aug 29;16(8):e68103. doi: 10.7759/cureus.68103. eCollection 2024 Aug.
5
Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review.欧盟对低收入和中等收入国家药品可及性的影响：一项范围综述
Lancet Reg Health Eur. 2021 Oct 7;9:100219. doi: 10.1016/j.lanepe.2021.100219. eCollection 2021 Oct.
6
Analysing the EU's collective securitisation moves towards China.分析欧盟针对中国的集体证券化举措。
Asia Eur J. 2022;20(2):195-216. doi: 10.1007/s10308-021-00640-4. Epub 2021 Oct 7.
7
Carbon and social impacts in the EU's consumption of fossil and mineral raw materials.欧盟对化石和矿物原材料消费中的碳影响及社会影响。
J Environ Manage. 2024 Oct;369:122291. doi: 10.1016/j.jenvman.2024.122291. Epub 2024 Sep 4.
8
China's impact on the European Union's Arctic policy: critical junctures, crossovers, and geographic shifts.中国对欧盟北极政策的影响：关键节点、交叉领域与地理转移
Asia Eur J. 2021;19(4):467-487. doi: 10.1007/s10308-021-00605-7. Epub 2021 May 29.
9
How and why pharmaceutical reforms contribute to universal health coverage through improving equitable access to medicines: a case of Ghana.医药改革如何以及为何通过改善药品公平可及性来促进全民健康覆盖：以加纳为例。
Front Public Health. 2023 Jul 7;11:1163342. doi: 10.3389/fpubh.2023.1163342. eCollection 2023.
10
Europeanisation of health systems: a qualitative study of domestic actors in a small state.卫生系统的欧洲化：对一个小国国内行为体的定性研究
BMC Public Health. 2016 Apr 14;16:334. doi: 10.1186/s12889-016-2909-0.
本文引用的文献
1
Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis: a commentary on the proposed EU pharma regulation.可转让数据独占性凭证并非解决抗菌药物研发危机的办法：对欧盟拟议药品法规的评论
BMJ Glob Health. 2024 Feb 28;9(2):e014605. doi: 10.1136/bmjgh-2023-014605.
2
Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovation.可转让独占权凭证：刺激抗生素创新的有缺陷激励措施。
Lancet. 2024 Jan 13;403(10422):e2-e4. doi: 10.1016/S0140-6736(23)00282-9. Epub 2023 Feb 9.
3
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担：系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
4
Shortage of essential antimicrobials: a major challenge to global health security.基本抗菌药物短缺：对全球卫生安全的重大挑战。
BMJ Glob Health. 2021 Nov;6(11). doi: 10.1136/bmjgh-2021-006961.
5
Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review.欧盟对低收入和中等收入国家药品可及性的影响：一项范围综述
Lancet Reg Health Eur. 2021 Oct 7;9:100219. doi: 10.1016/j.lanepe.2021.100219. eCollection 2021 Oct.
6
Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries.21 个高收入、中等收入和低收入国家的药品可及性和可负担性与心血管结局的关系。
BMJ Glob Health. 2020 Nov;5(11). doi: 10.1136/bmjgh-2020-002640.
7
The European Medicines Agency facilitates access to medicines in low- and middle-income countries.欧洲药品管理局为中低收入国家提供药品准入渠道。
Expert Rev Clin Pharmacol. 2020 Mar;13(3):321-325. doi: 10.1080/17512433.2020.1724782. Epub 2020 Feb 13.
8
Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.药品定价与采购的政策选择：低收入和中等收入国家面临的问题
Health Policy Plan. 2015 Mar;30(2):267-80. doi: 10.1093/heapol/czt105. Epub 2014 Jan 13.
Zotero 插件